NCT01013610View on ClinicalTrials.gov

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Mild Alzheimer's Disease
Interventions
DRUG

LNK-754

Escalating dose

DRUG

Placebo

Escalating dose

Trial Locations (7)

30308

Atlanta Center for Medical Research, Atlanta

32806

Compass Research, LLC, Orlando

33169

Elite Research Insitute, Miami

63118

St. Louis Clinical Trials, LC, St Louis

77074

Clinical Trial Network, Houston

85013

Dedicated Phase I, Phoenix

90806

Collaborative Neuroscience Network, Long Beach

Sponsors
All Listed Sponsors
lead

Link Medicine Corporation

INDUSTRY

NCT01013610 - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter